Medexus Pharmaceuticals (TSE:MDP - Get Free Report) was upgraded by equities researchers at Raymond James from an "outperform" rating to a "strong-buy" rating in a research report issued on Wednesday,BayStreet.CA reports. The firm presently has a C$4.00 price objective on the stock. Raymond James' price target would indicate a potential upside of 11.11% from the stock's current price.
Other analysts also recently issued reports about the company. Leede Financial set a C$8.25 price target on Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a research note on Monday, September 30th. Alliance Global Partners raised shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Two equities research analysts have rated the stock with a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Strong Buy" and a consensus target price of C$5.25.
Check Out Our Latest Research Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
MDP traded up C$0.14 on Wednesday, reaching C$3.60. The company had a trading volume of 76,606 shares, compared to its average volume of 63,531. The stock has a market cap of C$88.31 million, a P/E ratio of 72.00 and a beta of 1.96. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$3.60. The company's fifty day moving average is C$2.72 and its 200 day moving average is C$2.50.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Recommended Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
